About Cidara Therapeutics, Inc. - Common Stock (CDTX)
Cidara Therapeutics is a biopharmaceutical company focused on the development of innovative therapies to treat infectious diseases and cancer. The company is particularly known for its work in advancing its Cloudbreak platform, which aims to enhance the effectiveness of existing antifungal drugs by improving their delivery and targeting mechanisms. Cidara emphasizes the importance of addressing the growing challenge of multidrug-resistant pathogens and is actively engaged in the research and development of new treatments to combat these threats and improve patient outcomes. Through its strategic approach, Cidara strives to meet critical medical needs and contribute to the advancement of healthcare solutions. Read More
One biotech-focused investment firm cashed out of its stake in this drug developer as the stock soared—but seemingly missed out on a massive premium by mere weeks.
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Cidara Therapeutics, Inc. (NasdaqCM: CDTX) to Merck & Co., Inc. (NYSE: MRK). Under the terms of the proposed transaction, shareholders of Cidara will receive $221.50 in cash for each share of Cidara that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
BALA CYNWYD, Pa., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Cidara Therapeutics, Inc. (NASDAQ: CDTX) to Merck for $221.50 per share in cash is fair to Cidara shareholders.
With the new deal, Merck would gain access to CD388, currently in late-stage development, and designed to prevent influenza infection in individuals at higher risk of influenza complications.
Cidara Therapeutics Inc (NASDAQ:CDTX) shares are trading higher on Friday after the biotech company made a recent announcement about their presentation at the upcoming ESWI 2025 conference. JP Morgan also began coverage of the stock, assigning it an Overweight rating and setting a price target of $200.
